1 unchanged sentence
Trading Plans
−Removed: On March 11, 2025 , Howard G.
−Removed: Welgus , M.D., a member of our Board of Directors , entered into a Rule 10b5-1 trading plan , intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
+Added: On June 4, 2025 , Todd Franklin Watanabe , our Chief Executive Officer , entered into a Rule 10b5-1 trading plan , intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
The plan provided for the potential sale of up to 135,000 shares of common stock held by Mr.
−Removed: Welgus, the potential exercise and sale of up to 29,538 options, as well as the potential sale of 10,139 shares resulting from RSUs vesting between June 16, 2025 and May 29, 2026 .
+Added: Watanabe between October 1, 2025 and September 30, 2026 .
+Added: On June 6, 2025 , Masaru Matsuda , our General Counsel , entered into a Rule 10b5-1 trading plan , intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
+Added: The plan provided for the potential sale of up to 83,126 shares of common stock held by Mr.
+Added: Matsuda between September 4, 2025 and September 4, 2026 .
Number Description of Document Incorporated by Reference Form Date Number Filed/Furnished Herewith
7 unchanged sentences
S-1/A 1/21/20 4.2
−Removed: 10.1 Severance & Change in Control Agreement, dated April 10, 2025, by and between the Re gistrant and Latha Vairavan .
+Added: Manufacturing Supply Agreement, dated as of November 8, 2023 , by and between the Registrant and Bo ra Pharmaceuticals Services Inc.
+Added: Amendment No.
+Added: 1 to the Manufacturing Supply Agreement, dated as of March 22 , 2024 , by and between the Registra nt and Bora Pharmaceuticals Services Inc.
+Added: Amendment No.
+Added: 2 to the Manufacturing Supply Agreement, dated as of May 14, 2025 , by and between the Registrant and Bora Pharmaceuticals Services Inc.
+Added: 10.4 Severance & Change in Control Agreement, dated as of April 10, 2025, by and between the Registrant and Latha Vairavan .
+Added: 10.5 Amended and Restated Non-Employee Director Compensation Program.
31.1 Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities and Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
10 unchanged sentences
______________
−Removed: Registrant has omitted schedules and exhibits pursuant to Item 601(a)(5) of Regulation S-K.
+Added: Portions of this exhibit (indicated by asterisks) have been omitted pursuant to Regulation S-K, Item 601(b)(10) or certain schedules and attachments to this exhibit have been omitted pursuant to Regulation S-K, Item 601(a)(5).
+Added: Such omitted information is not material and would likely cause competitive harm to the registrant if publicly disclosed.
The Registrant agrees to furnish supplementally a copy of the omitted schedules and exhibits to the SEC upon request.
−Removed: † Registrant has omitted portions of the exhibit as permitted under Item 601(b)(10) of Regulation S-K.
* The certifications attached as Exhibit 32.1 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the SEC and are not to be incorporated by reference into any filing of Arcutis Biotherapeutics, Inc.
2 unchanged sentences
ARCUTIS BIOTHERAPEUTICS, INC.
−Removed: May 06, 2025 By:
+Added: August 06, 2025 By:
/s/ Todd Franklin Watanabe
2 unchanged sentences
(Principal Executive Officer)
−Removed: May 06, 2025 By:
+Added: August 06, 2025 By:
/s/ Latha Vairavan
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.